PriceTargets.com logo

Bright Minds Biosciences - DRUG Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $144.71
  • Forecasted Upside: 163.21%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$54.98 As of 10/30/2026 05:00 PM ET
▼ -1.71 (-3.02%)

This chart shows the closing price for DRUG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bright Minds Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRUG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRUG

Analyst Price Target is $144.71
▲ +163.21% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Bright Minds Biosciences in the last 3 months. The average price target is $144.71, with a high forecast of $220.00 and a low forecast of $80.00. The average price target represents a 163.21% upside from the last price of $54.98.

This chart shows the closing price for DRUG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Bright Minds Biosciences. This rating has held steady since September 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2026
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2026

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/15/2026Wolfe ResearchInitiated CoverageOutperform$150.00
9/28/2026Lifesci CapitalUpgradeStrong-Buy
9/15/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/20/2026OppenheimerDowngradeMarket Perform
8/20/2026BenchmarkReiterated RatingBuy ➝ Buy
8/19/2026HC WainwrightReiterated RatingBuy ➝ Buy$145.00
8/17/2026BTIG ResearchReiterated RatingBuy ➝ Buy$147.00
7/21/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
6/1/2026HC WainwrightReiterated RatingBuy ➝ Buy$145.00
5/20/2026Piper SandlerReiterated RatingOverweight ➝ Overweight$190.00 ➝ $220.00
4/13/2026Jefferies Financial GroupInitiated CoverageBuy$145.00
3/30/2026BTIG ResearchReiterated RatingBuy ➝ Buy$147.00
3/4/2026HC WainwrightBoost TargetBuy ➝ Buy$115.00 ➝ $145.00
2/17/2026BTIG ResearchReiterated RatingBuy ➝ Buy$147.00
2/13/2026Robert W. BairdSet Target$126.00
1/7/2026Robert W. BairdSet Target$142.00
1/6/2026BTIG ResearchBoost TargetBuy ➝ Buy$72.00 ➝ $147.00
1/2/2026Chardan CapitalReiterated RatingBuy ➝ Buy$80.00
12/30/2025HC WainwrightReiterated RatingBuy ➝ Buy$115.00
12/2/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
12/1/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
11/19/2025Chardan CapitalUpgradeStrong-Buy
10/13/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$85.00
9/8/2025BTIG ResearchInitiated CoverageBuy$72.00
8/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$85.00
7/2/2025Cantor FitzgeraldReiterated RatingOverweight
5/21/2025Chardan CapitalReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/13/2025Cantor FitzgeraldUpgradeStrong-Buy
5/13/2025TD CowenInitiated CoverageBuy
5/7/2025Chardan CapitalInitiated CoverageBuy$80.00
2/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
1/23/2025Piper SandlerInitiated CoverageOverweight$93.00
1/10/2025Cantor FitzgeraldInitiated CoverageOverweight
1/10/2025HC WainwrightInitiated CoverageBuy$85.00
11/25/2024Robert W. BairdUpgradeStrong-Buy
11/25/2024Robert W. BairdInitiated CoverageOutperform$75.00
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Bright Minds Biosciences logo
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Read More

Today's Range

Now: $54.98
Low: $54.96
High: $57.00

50 Day Range

MA: $59.18
Low: $48.25
High: $79.49

52 Week Range

Now: $54.98
Low: $47.23
High: $123.75

Volume

95,817 shs

Average Volume

145,334 shs

Market Capitalization

$535.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bright Minds Biosciences?

The following Wall Street analysts have issued stock ratings on Bright Minds Biosciences in the last year: Benchmark Co., BTIG Research, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Oppenheimer Holdings, Inc., Piper Sandler, Robert W. Baird, Wall Street Zen, Wolfe Research, and Zacks Research.
View the latest analyst ratings for DRUG.

What is the current price target for Bright Minds Biosciences?

0 Wall Street analysts have set twelve-month price targets for Bright Minds Biosciences in the last year. Their average twelve-month price target is $144.71, suggesting a possible upside of 163.2%. Piper Sandler has the highest price target set, predicting DRUG will reach $220.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $80.00 for Bright Minds Biosciences in the next year.
View the latest price targets for DRUG.

What is the current consensus analyst rating for Bright Minds Biosciences?

Bright Minds Biosciences currently has 2 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DRUG.

What other companies compete with Bright Minds Biosciences?

Other companies that are similar to Bright Minds Biosciences include Trulieve Cannabis, Xeris Biopharma, Trevi Therapeutics, Mineralys Therapeutics and Urogen Pharma. Learn More about companies similar to Bright Minds Biosciences.

How do I contact Bright Minds Biosciences' investor relations team?

Bright Minds Biosciences' physical mailing address is 19 Vestry Street, New York, NY, 10013. The company's listed phone number is 64-7407-2515 and its investor relations email address is ir@localhost. The official website for Bright Minds Biosciences is brightmindsbio.com. Learn More about contacing Bright Minds Biosciences investor relations.